Susquehanna Portfolio Strategies
ABUS icon

Susquehanna Portfolio Strategies’s Arbutus Biopharma ABUS Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.27M Buy
263,685
+244,865
+1,301% +$1.08M 0.02% 527
2026
Q1 		$84.7K Buy
+18,820
New +$82.3K ﹤0.01% 939

Other funds holding ABUS

Two Seas Capital
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Rubric Capital Management (New York)
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Susquehanna Portfolio Strategies's ABUS Position: Q2 2026 in Review

Susquehanna Portfolio Strategies increased its Arbutus Biopharma (ABUS) stake by 1,301% in Q2 2026, buying an estimated $1.08M and bringing the position to 263,685 shares worth $1.27M. The position accounts for 0.02% of the portfolio, ranked #527.

Susquehanna Portfolio Strategies first reported a position in ABUS in Q1 2026 and has held it in 2 quarters since. 176 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • Susquehanna Portfolio Strategies held 263,685 shares of Arbutus Biopharma worth $1.27M as of Q2 2026.
  • Susquehanna Portfolio Strategies bought 244,865 Arbutus Biopharma shares in Q2 2026, an estimated $1.08M.
  • Arbutus Biopharma made up 0.02% of Susquehanna Portfolio Strategies's portfolio in Q2 2026, its #527 holding.
  • Susquehanna Portfolio Strategies first reported a position in Arbutus Biopharma in Q1 2026 and has held it in 2 quarters since.
  • 176 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Susquehanna Portfolio Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.